NIKKEI 225
37,872.49 -587.59 (-1.53%) HANG SENG
17,133.85 -67.42 (-0.39%) CRUDE OIL
82.59 -0.22 (-0.27%) GOLD FUTURES
2,331.50 -6.90 (-0.30%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,413.49 -2,176.11 (-4.06%)
Novartis AG (0QLR.IL)
| Previous close | 89.58 |
| Open | 0.00 |
| Bid | 87.53 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,951,342 |
| Market cap | 205.83B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 27.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.20 (3.78%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- Insider Monkey
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript April 23, 2024 Novartis AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and Live Webcast. […]
- Benzinga
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugm
